Verinurad 9 mg+Febuxostat 80 mg + Placebo
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Hyperuricemia
Conditions
Hyperuricemia, Albuminuria, Type 2 Diabetes
Trial Timeline
May 18, 2017 → Aug 13, 2018
NCT ID
NCT03118739About Verinurad 9 mg+Febuxostat 80 mg + Placebo
Verinurad 9 mg+Febuxostat 80 mg + Placebo is a phase 2 stage product being developed by AstraZeneca for Hyperuricemia. The current trial status is completed. This product is registered under clinical trial identifier NCT03118739. Target conditions include Hyperuricemia, Albuminuria, Type 2 Diabetes.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03118739 | Phase 2 | Completed |
Competing Products
20 competing products in Hyperuricemia